Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2403179
Max Phase: Preclinical
Molecular Formula: C44H38I4N8
Molecular Weight: 678.84
Molecule Type: Unknown
Associated Items:
ID: ALA2403179
Max Phase: Preclinical
Molecular Formula: C44H38I4N8
Molecular Weight: 678.84
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-]
Standard InChI: InChI=1S/C44H37N8.4HI/c1-49-21-13-29(14-22-49)41-33-5-7-35(45-33)42(30-15-23-50(2)24-16-30)37-9-11-39(47-37)44(32-19-27-52(4)28-20-32)40-12-10-38(48-40)43(36-8-6-34(41)46-36)31-17-25-51(3)26-18-31;;;;/h5-28H,1-4H3,(H,45,46,47,48);4*1H/q+3;;;;/p-3/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-;;;;
Standard InChI Key: IWUSKFYHLANXSV-GVHKZQBISA-K
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 678.84 | Molecular Weight (Monoisotopic): 678.3197 | AlogP: 6.62 | #Rotatable Bonds: 4 |
Polar Surface Area: 72.88 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 4.66 | CX LogP: -9.42 | CX LogD: -9.42 |
Aromatic Rings: 7 | Heavy Atoms: 52 | QED Weighted: 0.21 | Np Likeness Score: 0.07 |
1. Alves E, Faustino MA, Tomé JP, Neves MG, Tomé AC, Cavaleiro JA, Cunha A, Gomes NC, Almeida A.. (2013) Nucleic acid changes during photodynamic inactivation of bacteria by cationic porphyrins., 21 (14): [PMID:23719285] [10.1016/j.bmc.2013.04.065] |
2. Slomp AM, Barreira SMW, Carrenho LZB, Vandresen CC, Zattoni IF, Ló SMS, Dallagnol JCC, Ducatti DRB, Orsato A, Duarte MER, Noseda MD, Otuki MF, Gonçalves AG.. (2017) Photodynamic effect of meso-(aryl)porphyrins and meso-(1-methyl-4-pyridinium)porphyrins on HaCaT keratinocytes., 27 (2): [PMID:27956348] [10.1016/j.bmcl.2016.11.094] |
3. Le Guern F, Ouk TS, Ouk C, Vanderesse R, Champavier Y, Pinault E, Sol V.. (2018) Lysine Analogue of Polymyxin B as a Significant Opportunity for Photodynamic Antimicrobial Chemotherapy., 9 (1): [PMID:29348804] [10.1021/acsmedchemlett.7b00360] |
4. Sobotta L, Skupin-Mrugalska P, Piskorz J, Mielcarek J.. (2019) Porphyrinoid photosensitizers mediated photodynamic inactivation against bacteria., 175 [PMID:31096157] [10.1016/j.ejmech.2019.04.057] |
5. Janas K, Boniewska-Bernacka E, Dyrda G, Słota R.. (2021) Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer., 30 [PMID:33341498] [10.1016/j.bmc.2020.115926] |
Source(1):